BrainsWay Announces Presentations at Upcoming Investor Conferences

CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

Presentation Details:

H.C. Wainwright 22nd Annual Global Investment ConferenceDate:                     Tuesday, September 15, 2020Time:                     2:00pm Eastern Time

Cantor Fitzgerald Virtual Global Healthcare ConferenceDate:                     Tuesday, September 15, 2020Time:                     10:00am Eastern Time

About BrainsWayBrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit www.brainsway.com

Contacts:BrainsWay:Judy HuberSVP and Chief Financial Officer[email protected]

Investors:Bob YedidLifeSci Advisors646-597-6989[email protected]

You May Also Be Interested In

• Brainsway (BWAY) PT Raised to $19 at H.C. Wainwright
• Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Third Quarter Common Stock Distribution of $0.1503 Per Share
• Mr. Ghyslain Rivard Files an Early Warning Report